



## Press Release

---

### **Oncobit bids farewell to Dr. Tomas Hruz and welcomes Prof. Mitch Levesque and Bram Goorden, MBA to the Board of Directors**

**Zurich, Switzerland - 21.06.2024** - Oncobit, a pioneer in precision cancer monitoring solutions, is pleased to announce changes to its Board of Directors. With the achievement of CE marking for our products and first revenues in Europe, the company focus shifts from product validation to clinical and commercial expansion. Following this shift the changes to the board composition, pave the way for the company's future success. The whole Oncobit team extends heartfelt gratitude to Dr. Tomas Hruz for his invaluable contributions in the areas of bioinformatic analyses and intellectual property and warmly welcomes Prof. Mitch Levesque and Bram Goorden, MBA as new members.

After years of dedicated service, Dr. Tomas Hruz has decided to step down from his position on the Board of Directors. As a co-founder of Oncobit, Dr. Hruz has played a critical role in guiding and managing Oncobit through its initial stages. His support and insights have been instrumental in the success of Oncobit's innovative cancer monitoring solutions and Oncobit expresses its deepest appreciation for his dedication and work.

Oncobit is delighted to welcome two esteemed professionals to its Board of Directors: Prof. Mitch Levesque and Bram Goorden. Their wealth of experience and expertise in clinical cancer research and the health care market will help take Oncobit to the next level.

Prof. Mitch Levesque is a co-founder of Oncobit and a renowned expert in skin cancer research, currently serving as a Full Professor of Experimental Skin Cancer Research at the University of Zurich. He holds the position of Scientific Department Co-Leader in the Department of Dermatology at the University Hospital of Zurich and has a distinguished academic background, with a PhD in Genetics & Genomics from Duke University. He has led ground-breaking research initiatives with a focus on clinical cancer biomarkers including public private partnerships with biopharma companies. His scientific expertise and leadership will be crucial in guiding Oncobit's future research and clinical strategies.

Bram Goorden, MBA brings over 20 years of leadership experience in the BioPharma and precision medicine sector to Oncobit. He held prominent roles, including COO at Eagle Genomics and SOPHiA Genetics, where he was instrumental in scaling companies and driving innovation in healthcare. During his tenure as President of International Business at Foundation Medicine Inc. the company's expanded its global presence in precision medicine, and as CEO of Prometheus Labs he helped with its integration into Nestle Health Science (NHSc). Mr Goorden's knowledge of the healthcare market, as well as his experience in navigating complex regulatory environments and fostering global partnerships, will be invaluable as Oncobit enters new



markets, further expands its market presence, and establishes new cancer monitoring technologies in clinical trials and clinical routine.

#### About Oncobit

Oncobit, a MedTech spin-off from the University of Zurich, is dedicated to transforming cancer monitoring and enabling personalized patient care through cutting-edge technologies. The company's innovative solution, the Oncobit™ PM platform, consists of proprietary digital PCR reagents and software that enables robust and standardized data analysis and interpretation. It offers highly accurate and sensitive cancer monitoring, providing clinicians with critical molecular insights for optimal therapy management to improve patient outcomes and reduce healthcare costs.

#### Web links:

<https://oncobit.com>

#### Contact:

Oncobit AG  
Dr. Björn Biedermann, CBO, Oncobit  
bjoern.biedermann@oncobit.com  
+41 78 256 99 56